Paul Peter Tak, MD PhD FMedSci

Paul Peter Tak, MD PhD FMedSci has an extensive work experience in the medical field. Paul Peter began their career in 2012 as an Honorary Senior Visiting Fellow at the University of Cambridge. In 2014, they were appointed Honorary Professor of Rheumatology at Ghent University. In 2018, they became a Director, Board of Directors, and Co-founder at Sitryx, and a Board Member at the Eureka Institute for Translational Medicine. In 2019, they joined the Board of Trustees at the Lorna & Yuti Chernajovsky Biomedical Research Foundation. In 2020, they were appointed Chair of the Strategic Priorities Fund Multimorbidity Steering Group (MRC, ESRC, NIHR), and Director, Board of Directors at both Candel Therapeutics and Citryll. Paul Peter is also President, CEO, and Board Director at Candel Therapeutics, where they are working to shift the cancer treatment paradigm. Lastly, they were appointed Chair of the Multimorbidity Clusters Programmes Steering Group at MRC, ESRC, and NIHR in 2022.

Paul Peter Tak, MD PhD FMedSci began their education in 1972 at Comenius College, where they graduated with a V.W.O. (Cum laude). In 1979, they completed their MD (Cum laude) at Vrije Universiteit Amsterdam (VU Amsterdam). From 1987 to 1993, they studied Internal Medicine at Leiden University, graduating with a degree in Internist. Paul Peter then went on to earn a PhD in Rheumatology from Leiden University in 1990, and a degree in Rheumatologist in 1996.